Clinical Trial Update: Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients [Phase 3]

View source ↗

Summary

A Phase 3 esophageal pH study evaluating Compound Sodium Alginate Double Action Chewable Tablets in patients with gastroesophageal reflux disease has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Compound Sodium Alginate Double Action Chewable Tablets (sodium alginate)

Snippet

Sponsor: Reckitt Benckiser Healthcare (UK) Limited | Conditions: Gastroesophageal Reflux Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-04-29